Annual Report for Fiscal Year 2025 - This is Johnson & Johnson's Form 10-K annual report filed on February 11, 2026, covering the fiscal year ended December 28, 2025, disclosing comprehensive financial performance, business operations, and risk factors for the pharmaceutical and healthcare company. Financial Structure and Debt Instruments - The filing details J&J's debt portfolio including…

Our analysis rates this filing CAUTIOUS. The elevated concern level (6.8/10) reflects a company managing multiple material headwinds but not facing imminent failure. The talc litigation represents the most significant concern - the explicit 33% loss contingency accrual indicates management has moved…

Concern level: HIGH (6.8/10). Key factors: Talc litigation with explicit 33% loss contingency accrual - material unresolved liability with historical precedent for multi-billion dollar settlements creating significant downside risk; Intangible asset impairment charges recorded in 2025 indicating write-downs of acquired assets and potential integration challenges with recent M&A activity (Yellow…

Notable risk changes: Talc litigation contingency accrual explicitly quantified at 33% loss probability - represents material unresolved liability that could result in significant settlements or judgments; Intangible asset impairment charges recorded in 2025 indicate write-downs of acquired assets, suggesting integration challenges or underperformance of recent M&A activity (Yellow Jersey Therapeutics acquisition…

The model predicts JNJ will outperform the S&P 500 by about 0.0% over 30 days (model confidence 50%). This is model analysis for research, not investment advice.